2016年美国生殖医学协会《中重度卵巢过度刺激综合征的预防和治疗的临床指南》解读

doi:10.16150/j.1671-2870.2017.03.005

摘要/Abstract

中图分类号:

R715.2

牛志宏. 2016年美国生殖医学协会《中重度卵巢过度刺激综合征的预防和治疗的临床指南》解读[J]. 诊断学理论与实践, 2017, 16(03): 260-263.

[1] Practice Committee of the American Society for Reproductive Medicine. Electronic address: ASRM@asrm.org; Practice Committee of the American Society for Reproductive Medicine. Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline[J]. Fertil Steril,2016,106(7):1634-1647.
[2] Lee TH, Liu CH, Huang CC, et al.Serum anti-Müllerian hormone and estradiol levels as predictors of ovarian hyperstimulation syndrome in assisted reproduction technology cycles[J]. Hum Reprod,2008,23(1):160-167.
[3] Kahnberg A, Enskog A, Brännström M, et al.Prediction of ovarian hyperstimulation syndrome in women under-going in vitro fertilization[J]. Acta Obstet Gynecol Scand,2009,88(12):1373-1381.
[4] Papanikolaou EG, Pozzobon C, Kolibianakis EM, et al.Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles[J]. Fertil Steril,2006,85(1):112-120.
[5] Toftager M, Bogstad J, Bryndorf T, et al.Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles[J]. Hum Reprod,2016,31(6):1253-1264.
[6] Al-Inany HG, Youssef MA, Aboulghar M, et al. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology[J]. Cochrane Database Syst Rev,2011,(5):CD001750.
[7] Youssef MA, Van der Veen F, Al-Inany HG, et al. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology[J]. Cochrane Database Syst Rev,2014,(10):CD008046.
[8] Meyer L, Murphy LA, Gumer A, et al.Risk factors for a suboptimal response to gonadotropin-releasing hormone agonist trigger during in vitro fertilization cycles[J]. Fertil Steril,2015,104(3):637-642.
[9] Várnagy A, Bódis J, Mánfai Z, et al.Low-dose aspirin therapy to prevent ovarian hyperstimulation syndrome[J]. Fertil Steril,2010,93(7):2281-2284.
[10] Revelli A, Dolfin E, Gennarelli G, et al.Low-dose acetylsalicylic acid plus prednisolone as an adjuvant treatment in IVF: a prospective, randomized study[J]. Fertil Steril,2008,90(5):1685-1691.
[11] Palomba S, Falbo A, La Sala GB.Effects of metformin in women with polycystic ovary syndrome treated with gonadotrophins for in vitro fertilisation and intracytoplasmic sperm injection cycles: a systematic review and meta-analysis of randomised controlled trials[J]. BJOG,2013, 120(3):267-276.
[12] Huang X, Wang P, Tal R, et al.A systematic review and meta-analysis of metformin among patients with polycystic ovary syndrome undergoing assisted reproductive technology procedures[J]. Int J Gynaecol Obstet,2015, 131(2):111-116.
[13] Amir H, Yaniv D, Hasson J, et al.Cabergoline for redu-cing ovarian hyperstimulation syndrome in assisted reproductive technology treatment cycles. A prospective randomized controlled trial[J]. J Reprod Med,2015,60(1-2):48-54.
[14] Leitao VM, Moroni RM, Seko LM, et al.Cabergoline for the prevention of ovarian hyperstimulation syndrome: systematic review and meta-analysis of randomized controlled trials[J]. Fertil Steril,2014,101(3):664-675.
[15] Youssef MA, Al-Inany HG, Evers JL, et al. Intra-venous fluids for the prevention of severe ovarian hyperstimulation syndrome[J]. Cochrane Database Syst Rev,2011,(2):CD001302.
[16] El-Khayat W, Elsadek M.Calcium infusion for the prevention of ovarian hyperstimulation syndrome: a double-blind randomized controlled trial[J]. Fertil Steril,2015, 103(1):101-105.
[17] Naredi N, Karunakaran S.Calcium gluconate infusion is as effective as the vascular endothelial growth factor antagonist cabergoline for the prevention of ovarian hyperstimulation syndrome[J]. J Hum Reprod Sci,2013,6(4):248-252.
[18] Qublan HS, Al-Taani MI, Megdadi MF, et al.Multiple transvaginal ascitic fluid aspirations improves the clinical and reproductive outcome in patients undergoing in vitro fertilisation treatment complicated by severe early ovarian hyperstimulation syndrome[J]. J Obstet Gynaecol,2012, 32(4):379-382.

2016年美国生殖医学协会《中重度卵巢过度刺激综合征的预防和治疗的临床指南》解读

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	陈志敏, 何浩岚. 艾滋病合并马尔尼菲篮状菌病的诊治现状[J]. 诊断学理论与实践, 2022, 21(04): 425-430.
[2]	施霞, 马鑫, 王珍燕, 张晖, 刘少军. 32例人类免疫缺陷病毒感染合并慢性肾病患者的临床病理特征及随访结果分析[J]. 诊断学理论与实践, 2022, 21(04): 437-443.
[3]	陈宏, 沈银忠. 人类免疫缺陷病毒感染/艾滋病合并结核病的诊治进展[J]. 诊断学理论与实践, 2022, 21(04): 530-534.
[4]	李佳, 吕良敬. 靶向治疗时代议自身免疫病的感染挑战[J]. 诊断学理论与实践, 2022, 21(03): 299-303.
[5]	中华医学会内分泌学分会. 新型冠状病毒肺炎疫情下骨质疏松症管理专家建议[J]. 诊断学理论与实践, 2022, 21(02): 133-135.
[6]	张祎博, 吴文娟, 毕宇芳, 景峰, 顾志冬, 杨之涛, 尚寒冰, 林靖生, 陈尔真. 大型方舱医院感染预防与控制体系的建设和实践探索[J]. 诊断学理论与实践, 2022, 21(02): 165-168.
[7]	庄蕾, 高卫益. 新型冠状病毒肺炎疫情期间非定点医疗机构“分区管理”策略[J]. 诊断学理论与实践, 2022, 21(02): 245-247.
[8]	王亦晨, 周剑平, 杨振华, 王敏慧, 刘佳, 倪语星, 张祎博, 石大可, 徐玉敏. 新型冠状病毒肺炎救治临时定点医院工作人员医院感染防控管理方案[J]. 诊断学理论与实践, 2022, 21(02): 270-272.
[9]	魏文石. 直面我国阿尔茨海默病诊治的挑战——《中国阿尔茨海默病报告2021》解读[J]. 诊断学理论与实践, 2022, 21(01): 5-7.
[10]	付朝伟. 阿尔茨海默病重在预防——《中国阿尔茨海默病报告2021》解读[J]. 诊断学理论与实践, 2022, 21(01): 8-11.
[11]	罗雅方, 徐倩玥, 余红. 尘螨在特应性皮炎中的致病机制及相关免疫治疗应用研究进展[J]. 诊断学理论与实践, 2021, 20(06): 592-595.
[12]	苏长青. 从基础研究到临床转化应用谈肝癌的诊治进展[J]. 诊断学理论与实践, 2021, 20(05): 427-433.
[13]	周艺, 杨莉. 粒细胞-巨噬细胞集落刺激因子在肿瘤免疫治疗中的作用机制及临床应用进展[J]. 诊断学理论与实践, 2021, 20(04): 407-413.
[14]	林芙君, 蒋更如. 奥尔波特综合征的疾病谱扩展对相关疾病诊断、筛查和治疗的启示[J]. 诊断学理论与实践, 2021, 20(03): 245-250.
[15]	陈英杰, 刘霄宇, 吴卓卓, 王忠敏. PBL教学模式在本科生教学下肢血管介入治疗课程中的应用[J]. 诊断学理论与实践, 2021, 20(03): 302-304.